VIA
SYRE icon

Virtus Investment Advisers’s Spyre Therapeutics SYRE Stock Holding History

Virtus Investment Advisers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Sell
4,050
-4,060
-50% -$296K 0.08% 337
2026
Q1 		$409K Buy
8,110
+197
+2% +$7.43K 0.11% 243
2025
Q4 		$259K Buy
7,913
+1,488
+23% +$38.9K 0.07% 313
2025
Q3 		$108K Buy
6,425
+1,115
+21% +$18.2K 0.03% 417
2025
Q2 		$79.5K Sell
5,310
-1,551
-23% -$22.9K 0.03% 424
2025
Q1 		$111K Buy
+6,861
New +$143K 0.03% 406

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Virtus Investment Advisers's SYRE Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Spyre Therapeutics (SYRE) stake by 50% in Q2 2026, selling an estimated $296K and leaving 4,050 shares worth $360K. The position accounts for 0.08% of the portfolio, ranked #337.

Virtus Investment Advisers first reported a position in SYRE in Q1 2025 and has held it in 6 quarters since. The position peaked at $409K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Virtus Investment Advisers held 4,050 shares of Spyre Therapeutics worth $360K as of Q2 2026.
  • Virtus Investment Advisers sold 4,060 Spyre Therapeutics shares in Q2 2026, an estimated $296K.
  • Spyre Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #337 holding.
  • Virtus Investment Advisers first reported a position in Spyre Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Virtus Investment Advisers's Spyre Therapeutics position peaked at $409K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.